SRPT (US) share price forecast & AI signal — Sarepta Therapeutics, Inc
Week of 2026-10-30 · Healthcare
Exact confidence, 1-week / 1-month / 3-month breakdown, plain-English AI write-up, bull-vs-bear debate, support & resistance.
Get 5 free tokens — no card Already a member? Open the full analysisWhat the model sees in SRPT
Sarepta Therapeutics, Inc is a Healthcare stock listed on the US. For the week of 2026-10-30 the ACE machine-learning model rates it a SELL with moderate confidence, based on technical indicators and the stock's own historical patterns across three time horizons. The direction is updated every model run.
About Sarepta Therapeutics, Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping;...
Recent closes
| Date | Close |
|---|---|
| 2026-11-06 | $17.82 |
| 2026-11-05 | $17.57 |
| 2026-11-04 | $18.99 |
| 2026-11-03 | $18.54 |
| 2026-11-02 | $18.32 |
| 2026-10-30 | $18.62 |
| 2026-10-29 | $19.23 |
SRPT FAQ
Is Sarepta Therapeutics, Inc (SRPT) a buy or sell this week?
The ACE Stock Bots machine-learning model rates SRPT a SELL for the week of 2026-10-30 with moderate confidence. The exact confidence and the 1-week, 1-month and 3-month breakdown are free with a signup (5 analysis tokens, no card).
What is the AI share price forecast for SRPT?
Every week the model scores SRPT across three horizons using technical indicators and the stock's own historical patterns. An AI then writes a plain-English summary with support and resistance levels, and a bull analyst and a bear analyst argue the case.
Is this financial advice?
No. ACE Stock Bots provides general information generated by software. It does not consider your objectives, financial situation or needs. Read the disclaimer and consider licensed advice before acting.
Other Healthcare stocks on the US
This week's top US picks · All US stocks
Signals are generated by software for general information only and are not a recommendation to buy or sell. See the disclaimer.